KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Non-Current Deffered Revenue (2016 - 2026)

Biocryst Pharmaceuticals filings provide 9 years of Non-Current Deffered Revenue readings, the most recent being $54000.0 for Q4 2018.

  • On a quarterly basis, Non-Current Deffered Revenue fell 65.16% to $54000.0 in Q4 2018 year-over-year; TTM through Dec 2018 was $54000.0, a 65.16% decrease, with the full-year FY2018 number at $54000.0, down 65.16% from a year prior.
  • Non-Current Deffered Revenue hit $54000.0 in Q4 2018 for Biocryst Pharmaceuticals, down from $81000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $9.7 million in Q4 2015 to a low of $54000.0 in Q4 2018.
  • Median Non-Current Deffered Revenue over the past 5 years was $2.0 million (2014), compared with a mean of $3.4 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: skyrocketed 2420.13% in 2017 and later crashed 98.59% in 2018.
  • Biocryst Pharmaceuticals' Non-Current Deffered Revenue stood at $3.6 million in 2014, then surged by 172.35% to $9.7 million in 2015, then decreased by 15.4% to $8.2 million in 2016, then crashed by 98.11% to $155000.0 in 2017, then crashed by 65.16% to $54000.0 in 2018.
  • The last three reported values for Non-Current Deffered Revenue were $54000.0 (Q4 2018), $81000.0 (Q3 2018), and $107000.0 (Q2 2018) per Business Quant data.